Add time:08/04/2019         Source:sciencedirect.com

Centchroman is a non-steroidal oral contraceptive and has been found to be a candidate drug for breast cancer exhibiting partial to complete remission of lesions in 40.5% of breast cancer patients. The therapeutic efficacy of centchroman was monitored alone and together with glycine soya on growth of 7,12-dimethylbenz[α]anthracene-induced breast tumor in rat. The tumor regression was monitored at different doses of centchroman alone ranging from 0 to 10 mg kg−1 and with glycine soya from 1 × 104 to 5 × 104 mg kg−1 per day until 5 weeks treatment. An optimum tumor treatment opus was established with varying treatment parameters including doses of therapeutic agents and treatment period. The tumors were found to be static with a strong anti-estrogenic effect. Overall our study shows that both centchroman and glycine soya alone and jointly combat with breast cancer.

We also recommend Trading Suppliers and Manufacturers of 4-methoxy-7,12-dimethylbenz(a)anthracene (cas 16277-49-9). Pls Click Website Link as below: cas 16277-49-9 suppliers